File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Safety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination

TitleSafety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination
Authors
KeywordsInfluenza A/H7N9
Prime-boost
Vaccines
Pandemic
Avian
Influenza
Issue Date2019
PublisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine
Citation
Vaccine, 2019, v. 37 n. 19, p. 2561-2568 How to Cite?
AbstractBackground: Influenza A/H7N9 viruses are undergoing antigenic drift since their emergence in 2013, and vaccination strategies are needed for pandemic preparedness. Two doses of adjuvanted monovalent inactivated influenza A/H7N9 vaccine (IIV1 A/H7N9) are needed for optimal serological responses. However, administering 2 doses in a pandemic setting might be challenging. We evaluated the immunogenicity of “boosting” with IIV1 A/H7N9 in subjects “primed” 8 years previously with IIV1 A/H7N7. Methods: We administered 1 booster dose containing 45 mcg of IIV1 A/H7N9 hemagglutinin to 17 recipients of 2 prior doses of IIV1 A/H7N7, and to 10 influenza A/H7-naïve subjects. We tested their post-boosting sera for antibodies (Ab) against homologous influenza A/H7N9 using a hemagglutination inhibition assay; and compared their Ab titers to those in stored sera from recipients of AS03-adjuvanted IIV1 A/H7N9 against 9 strains of influenza A/H7N9 viruses. Results: The percentage of subjects with Ab titers ≥40 on Days 9 and 29 post boosting, respectively, was 65% and 41% in primed subjects and 10% and 0% in unprimed subjects. The Ab titers in recipients of AS03-adjuvanted IIV1 A/H7N9 were higher than those in the prime-boost group against a panel of influenza A/H7N9 viruses, except for 2 highly pathogenic strains. Conclusions: Priming with IIV1 A/H7 results in serological responses following a delayed boost with 1 dose of unadjuvanted IIV1 A/H7N9, despite lack of antibody response after the prime. Optimizing prime-boost approaches would benefit pandemic preparedness. ClinicalTrials.gov identifier: NCT02586792.
Persistent Identifierhttp://hdl.handle.net/10722/276131
ISSN
2019 Impact Factor: 3.143
2015 SCImago Journal Rankings: 2.044
PubMed Central ID
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorEl Sahly, HM-
dc.contributor.authorAtmar, RL-
dc.contributor.authorPatel, SM-
dc.contributor.authorBellamy, A-
dc.contributor.authorLiu, L-
dc.contributor.authorHong, W-
dc.contributor.authorZhu, H-
dc.contributor.authorGuan, Y-
dc.contributor.authorKeitel, WA-
dc.contributor.authorthe DMID 13-0033 Vaccine Study Group-
dc.date.accessioned2019-09-10T02:56:35Z-
dc.date.available2019-09-10T02:56:35Z-
dc.date.issued2019-
dc.identifier.citationVaccine, 2019, v. 37 n. 19, p. 2561-2568-
dc.identifier.issn0264-410X-
dc.identifier.urihttp://hdl.handle.net/10722/276131-
dc.description.abstractBackground: Influenza A/H7N9 viruses are undergoing antigenic drift since their emergence in 2013, and vaccination strategies are needed for pandemic preparedness. Two doses of adjuvanted monovalent inactivated influenza A/H7N9 vaccine (IIV1 A/H7N9) are needed for optimal serological responses. However, administering 2 doses in a pandemic setting might be challenging. We evaluated the immunogenicity of “boosting” with IIV1 A/H7N9 in subjects “primed” 8 years previously with IIV1 A/H7N7. Methods: We administered 1 booster dose containing 45 mcg of IIV1 A/H7N9 hemagglutinin to 17 recipients of 2 prior doses of IIV1 A/H7N7, and to 10 influenza A/H7-naïve subjects. We tested their post-boosting sera for antibodies (Ab) against homologous influenza A/H7N9 using a hemagglutination inhibition assay; and compared their Ab titers to those in stored sera from recipients of AS03-adjuvanted IIV1 A/H7N9 against 9 strains of influenza A/H7N9 viruses. Results: The percentage of subjects with Ab titers ≥40 on Days 9 and 29 post boosting, respectively, was 65% and 41% in primed subjects and 10% and 0% in unprimed subjects. The Ab titers in recipients of AS03-adjuvanted IIV1 A/H7N9 were higher than those in the prime-boost group against a panel of influenza A/H7N9 viruses, except for 2 highly pathogenic strains. Conclusions: Priming with IIV1 A/H7 results in serological responses following a delayed boost with 1 dose of unadjuvanted IIV1 A/H7N9, despite lack of antibody response after the prime. Optimizing prime-boost approaches would benefit pandemic preparedness. ClinicalTrials.gov identifier: NCT02586792.-
dc.languageeng-
dc.publisherElsevier Ltd. The Journal's web site is located at http://www.elsevier.com/locate/vaccine-
dc.relation.ispartofVaccine-
dc.subjectInfluenza A/H7N9-
dc.subjectPrime-boost-
dc.subjectVaccines-
dc.subjectPandemic-
dc.subjectAvian-
dc.subjectInfluenza-
dc.titleSafety and immunogenicity of an 8 year interval heterologous prime-boost influenza A/H7N7-H7N9 vaccination-
dc.typeArticle-
dc.identifier.emailZhu, H: zhuhch@hku.hk-
dc.identifier.emailGuan, Y: yguan@hkucc.hku.hk-
dc.identifier.authorityZhu, H=rp01535-
dc.identifier.authorityGuan, Y=rp00397-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1016/j.vaccine.2019.03.071-
dc.identifier.pmid30955980-
dc.identifier.pmcidPMC6519114-
dc.identifier.scopuseid_2-s2.0-85063760482-
dc.identifier.hkuros302418-
dc.identifier.volume37-
dc.identifier.issue19-
dc.identifier.spage2561-
dc.identifier.epage2568-
dc.identifier.isiWOS:000466248800006-
dc.publisher.placeUnited Kingdom-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats